Skip to main content
. 2023 Dec 12;16:3561–3574. doi: 10.2147/CCID.S416149

Figure 2.

Figure 2

Proportion of patients still on treatment with secukinumab after 42 months: (A) Cumulative proportion of patients. (B) Biologic-naïve and biologic-experienced patients. (C) HLA-Cw6–positive and HLA-Cw6–negative patients.